PCVX ▼ -1.9% - Vaxcyte, Inc.
$PCVX - Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte shares fell 1.9% following the company's announcement that it has narrowed its guidance for when it expects topline data from its VAX-31 OPUS-1 trial. While the company also appointed new Chief Medical and Chief Legal Officers, the tighter timeline for trial results appears to have weighed on the stock, likely reflecting investor concerns about the narrowed window or revised expectations around the data readout.
03-SEP-2026 04:08 PM ET
Share this post
More filings for $PCVX
PCVX ▲ +0.1% - Vaxcyte, Inc.Aug 27, 2026PCVX - Vaxcyte, Inc. - SEC Filing Update (11-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 11, 2026PCVX - Vaxcyte, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026PCVX - Vaxcyte, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $PCVX filing history →💬 Comments
Loading comments…
Leave a comment
